GO
Loading...

AstraZeneca PLC

More

  • Astrazenaca has rejected Pfizer's $106 billion bid for the company. CNBC's Meg Tirrell, and Tim Chiang, CRT Capital senior analyst, discuss Pfizer's "opportunistic" strategy, and m&a in the pharma industry.

  • *AstraZeneca rejects Pfizer's raised bid of $106 bln. Yet on the results front, LinkedIn Corp shares dropped 6.9 percent to $150.06, a day after the social networking company forecast 2014 revenue below Wall Street's expectations, the latest company to disappoint on sales this reporting period.

  • European stocks dip as investors book recent gains Friday, 2 May 2014 | 12:40 PM ET

    *Deutsche Telekom, Bouygues, Iliad up on M&A talk. Mergers and acquisitions continued to boost a number of sectors, with Deutsche Telekom up 1.1 percent on talk that Sprint Corp has approached banks to work out funding for its bid for T-Mobile US Inc, which is majority-owned by the German telecom operator.

  • *Astrazeneca rejects Pfizer's raised bid of $106 bln. While the report provided an encouraging read on the labor market, many market participants said Wall Street's gains over the week made further advances unlikely.

  • LONDON, May 2- U.S. drugmaker Pfizer Inc's effort to sweeten its bid for Britain's AstraZenaca Plc with commitments on research, manufacturing and jobs is claimed as a coup by the UK government, but many are deeply sceptical.

  • M&A helps keep European stock rally alive Friday, 2 May 2014 | 10:59 AM ET

    *Deutsche Telekom, Bouygues, Iliad up on M&A talk. Deutsche Telekom was the top gainer among European blue-chips. It rose 1.9 percent on talk Sprint Corp has approached banks to work out funding for its bid for T-Mobile US Inc, which is majority-owned by the German telecom operator.

  • *Astrazeneca rejects Pfizer's raised bid of $106 bln. The payrolls gain of 288,000 was the largest since January 2012 and beat Wall Street's expectations for an increase of just 210,000..

  • Pfizer $106.5B offer ‘inadequate’: AstraZeneca Friday, 2 May 2014 | 9:23 AM ET
    Pfizer

    AstraZeneca's board rejected a $106.5 billion bid from predator Pfizer just hours after it was received, arguing that it is too low.

  • AstraZeneca rejects new Pfizer bid     Friday, 2 May 2014 | 9:07 AM ET

    AstraZeneca has rejected Pfizer's sweetened bid claiming it undervalues the company. The "Squawk on the Street" news team shares their thoughts on the latest bid and the U.S. tax code.

  • U.S. stock index futures pointed to a slightly higher open on Wall Street, ahead of the government’s all-important non-farm payrolls jobs report.

  • LONDON, May 2- Britain's government said it was considering whether reassurances made by Pfizer over its potential takeover of AstraZeneca offered sufficient protection to maintain the country's life sciences sector and related jobs.

  • *Russia, Ukraine assets fall as crisis escalates. LONDON, May 2- Global markets traded cautiously on Friday, with uncertainty ahead of U.S. employment figures and tensions in Ukraine pushing the yield on 10- year German Bunds to the lowest in a year and leaving shares treading water. April non-farm payrolls report, due at 1230 GMT.

  • *Astrazeneca rejects Pfizer's raised bid of $106 bln. NEW YORK, May 2- U.S. stock index futures were little changed Friday on caution ahead of the key U.S. nonfarm payrolls report for April.

  • Early movers: AZN, PFE, CVS, EL, KRFT, LKND & more Friday, 2 May 2014 | 7:39 AM ET
    Traders on the floor of the New York Stock Exchange on Monday

    Some of the names on the move ahead of the open.

  • *AstraZeneca board rejects sweetened 50 stg/ shr offer. LONDON, May 2- U.S. drugmaker Pfizer Inc increased its offer for AstraZeneca Plc to 63 billion pounds on Friday, but the British company promptly rejected the proposal, which would create the world's biggest pharmaceuticals company.

  • *Deutsche Telekom rises on T-Mobile US bid speculation. The euro zone's blue-chip Euro STOXX 50 index dipped 0.3 percent to 3,187.72 points. Both the FTSEurofirst 300 and the Euro STOXX 50 have gained more than 2 percent since the start of 2014..

  • *AstraZeneca board rejects sweetened 50 stg/ shr offer. LONDON, May 2- U.S. drugmaker Pfizer Inc raised its offer for AstraZeneca Plc to 63 billion pounds on Friday, but the British company promptly rejected the proposal, which would create the world's biggest pharmaceuticals company.

  • Astrazeneca rejects latest Pfizer approach Friday, 2 May 2014 | 5:59 AM ET

    LONDON, May 2- AstraZeneca's board said on Friday it had rejected an improved $106 billion takeover offer from U.S. drugmaker Pfizer, saying the bid which was announced just hours ago undervalued the firm.

  • LONDON, May 2- Global markets traded cautiously on Friday as uncertainty ahead of U.S. employment figures and tensions in Ukraine pushed the yield on 10- year German Bunds to their lowest in a year. That, and an escalation in violence in eastern Ukraine between government forces and pro-Russian separatists, weighed on investor sentiment.

  • Takeover activity keeps European shares steady Friday, 2 May 2014 | 4:11 AM ET

    *Dt Telekom rises on T-Mobile US bid speculation. The euro zone's blue-chip Euro STOXX 50 index dipped 0.3 percent to 3,188.48 points. On Friday, Deutsche Telekom rose 1.9 percent, after Reuters reported that U.S. rival Sprint had met with banks ahead of a planned bid for T-Mobile US, which is 67 percent owned by Deutsche Telekom.